Axitinib: A Review in Advanced Renal Cell Carcinoma

[1]  J. Ansari,et al.  Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma , 2013, Biologics : targets & therapy.

[2]  B. Rini,et al.  Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors , 2011, Clinical Cancer Research.

[3]  R. Motzer,et al.  Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis , 2013, Journal of clinical pharmacology.

[4]  P. Petrou.  Cost-effectiveness analysis of axitinib through a probabilistic decision model , 2015, Expert opinion on pharmacotherapy.

[5]  T. Mukohara,et al.  Effect of axitinib (AG‐013736) on fatigue, thyroid‐stimulating hormone, and biomarkers: A phase I study in Japanese patients , 2010, Cancer science.

[6]  M. Atkins,et al.  DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1. , 2015 .

[7]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[8]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[9]  J. Larkin,et al.  Axitinib in advanced renal-cell carcinoma. , 2013, The Lancet. Oncology.

[10]  J. Manola,et al.  Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. , 2015 .

[11]  B. Rini,et al.  Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management , 2012 .

[12]  E. Jonasch,et al.  Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review. , 2015 .

[13]  K. Harada,et al.  Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib , 2015, International Journal of Clinical Oncology.

[14]  Ying Lu,et al.  AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. , 2007, Magnetic resonance imaging.

[15]  Yang Yao,et al.  Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. , 2013, British journal of clinical pharmacology.

[16]  J. Bellmunt,et al.  Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. , 2014, European journal of cancer.

[17]  R. Motzer,et al.  Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. , 2013, Clinical genitourinary cancer.

[18]  R. Motzer,et al.  Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib , 2015, Targeted Oncology.

[19]  H. Akaza,et al.  Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial , 2013, Japanese journal of clinical oncology.

[20]  B. Poland,et al.  Population pharmacokinetic analysis of axitinib in healthy volunteers. , 2014, British journal of clinical pharmacology.

[21]  R. Motzer,et al.  Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial , 2013, British Journal of Cancer.

[22]  J. Bergh,et al.  The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. , 2015, The oncologist.

[23]  B. Rini,et al.  Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma , 2015, Clinical Pharmacokinetics.

[24]  Ying Cheng,et al.  Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study , 2015, OncoTargets and therapy.

[25]  A. Poprach,et al.  2615 Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data , 2015 .

[26]  B. Hirsch,et al.  Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward? , 2014, Clinical advances in hematology & oncology : H&O.

[27]  V. Lokeshwar,et al.  Molecular Marker for Predicting Treatment Response in Advanced Renal Cell Carcinoma: Does the Promise Fulfill Clinical Need? , 2013, Current Urology Reports.

[28]  R. Motzer,et al.  Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial , 2014, Targeted Oncology.

[29]  R. Labadie,et al.  Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics , 2010, Investigational New Drugs.

[30]  E. Jonasch,et al.  Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. , 2015 .

[31]  R. Herbst,et al.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Benjamin M Yeh,et al.  Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[35]  U. Kuruganti,et al.  Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers , 2009, Cancer Chemotherapy and Pharmacology.

[36]  H. Miyake,et al.  MP39-20 MOLECULAR MECHANISM UNDERLYING CYTOTOXIC ACTIVITY OF AXITINIB IN SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA ACHN CELLS , 2015 .

[37]  H. Akaza,et al.  Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma , 2014, Cancer science.

[38]  E. Jonasch,et al.  Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. , 2013, The Lancet. Oncology.

[39]  R. Motzer,et al.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Motzer,et al.  Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. , 2015, Clinical genitourinary cancer.

[41]  R. Motzer,et al.  Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. , 2015, Clinical genitourinary cancer.

[42]  H. Akaza,et al.  Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. , 2011, European journal of cancer.

[43]  M. Fishman,et al.  Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  E. Porfiri,et al.  2600 Axitinib in second and further line for metastatic renal cell carcinoma (RCC): Real world data from 2 teaching hospitals in Birmingham, UK , 2015 .

[45]  R. Labadie,et al.  Axitinib plasma pharmacokinetics and ethnic differences , 2015, Investigational New Drugs.

[46]  J. Williams,et al.  Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics , 2012, European Journal of Clinical Pharmacology.

[47]  P. Hu,et al.  A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers. , 2011, International journal of clinical pharmacology and therapeutics.

[48]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[49]  N. Vogelzang,et al.  2509 Overall survival analysis from a randomised phase III trial of axitini vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma , 2015 .

[50]  C. Obasaju,et al.  PLS. plenary session , 2012 .

[51]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[52]  R. Labadie,et al.  Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers , 2012, Cancer Chemotherapy and Pharmacology.

[53]  Y. Pithavala,et al.  Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers , 2010, Investigational New Drugs.

[54]  R. Motzer,et al.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. , 2007, The Lancet. Oncology.

[55]  T. Mukohara,et al.  Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients , 2011, Investigational New Drugs.

[56]  E. Espinosa,et al.  Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action , 2012, Cancer and Metastasis Reviews.

[57]  B. Houk,et al.  Effect of axitinib on the QT interval in healthy volunteers , 2015, Cancer Chemotherapy and Pharmacology.

[58]  T. Choueiri,et al.  A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma. , 2014 .

[59]  G. Wilding,et al.  Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Lam,et al.  Novel approaches in the therapy of metastatic renal cell carcinoma , 2005, World Journal of Urology.

[61]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[62]  Y. Pithavala,et al.  Clinical Pharmacology of Axitinib , 2013, Clinical Pharmacokinetics.